N/A
N=265
Evaluation of 3 Versus 10 Days of Antibiotics in Skin Abscesses After Surgical Drainage
Skin Disease, Bacterial · Abscess
Bottom Line
View on ClinicalTrials.gov: NCT02024867 ↗Enrolled (actual)
265
Serious AEs
0.0%
Results posted
Sep 2014
Primary outcome: Primary: Treatment Failures — 9; 4 participants — p=0.25
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Trimethoprim-Sulfamethoxazole (Drug)
- Age
- Pediatric · 0+ yrs
- Sex
- All
- Sponsor
- Lucy Holmes, MD
- Primary completion
- Jan 2012
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Treatment Failures |
9; 4 | 0.25 |
| PRIMARY Treatment Failures Among Patients Infected With Methicillin-Resistant Staphylococcus Aureus |
8; 1 | 0.03 sig |
| PRIMARY Treatment Failures Among Patients Infected With Methicillin-Sensitive Staphylococcus Aureus |
1; 1 | >0.05 |
| SECONDARY Recurrent Skin Infections |
21; 9 | 0.02 sig |
| SECONDARY Recurrent Skin Infections Among Patients Infected With Methicillin-Resistant Staphylococcus Aureus |
8; 2 | 0.046 sig |
| SECONDARY Recurrent Skin Infections Among Patients Infected With Methicillin-Sensitive Staphylococcus Aureus |
7; 7 | >0.05 |
Summary
The objective of this study is to determine if there is a difference in treatment failures and recurrent skin infections when patients are given 3 or 10 days of antibiotics for uncomplicated skin abscesses after they have been surgically drained.
Eligibility Criteria
Inclusion Criteria
- patients presenting with a skin abscess that requires surgical drainage (induration ≥ 1 cm in diameter)
- minimally invasive surgical technique with the insertion of a subcutaneous drain can be utilized on the patient
Exclusion Criteria
- patients requiring immediate hospitalization
- patients who have received 2 or more doses of antibiotics in the previous 36 hours
- patients with diabetes, sickle-cell disease, an immuno-compromising disease, an underlying medical condition predisposing the patient to frequent hospitalizations or medical visits, or indwelling catheters or percutaneous medical devices
- patients with a concurrent, non-abscess infection
- patients with an allergy to Trimethoprim-sulfamethoxazole
Data sourced from ClinicalTrials.gov (NCT02024867). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.